| Akcea Therapeutics is a commercial stage biopharmaceutical company developing and commercializing medicines to treat patients. Co. is focused on commercializing its approved therapies, TEGSEDI and WAYLIVRA. TEGSEDI is indicated to treat adults with the polyneuropathy caused by hereditary transthyretin-mediated amyloidosis, and has been approved and launched in the United States, the European Union, and Canada as well as approved in Brazil. WAYLIVRA is indicated as an adjunct to diet to treat adult patients with genetically confirmed familial chylomicronemia syndrome, who are at high risk for pancreatitis, for whom response to diet and triglyceride lowering therapy has been inadequate. We show 15 historical shares outstanding datapoints in our coverage of AKCA's shares outstanding history.|
Understanding the changing numbers of AKCA shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like AKCA versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching AKCA by allowing them to research AKCA shares outstanding history
as well as any other stock in our coverage universe.